Innate Pharma SA (FR:IPH) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Innate Pharma SA has announced its selection for the 2024 ASH Annual Meeting, highlighting their progress with lacutamab and the SAR443579 asset, developed in collaboration with Sanofi. These advancements reflect Innate’s commitment to delivering new cancer treatments, particularly for lymphomas with high unmet needs. The company’s innovative approach and strategic partnerships position it as a significant player in the biotech sector.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
